In This Story
cbdMD Inc. (YCBD-12.59%) has submitted its annual report on Form 10-K for the fiscal year ended September 30, 2024 filing.
The filing reports total net sales of $19.5 million, a decrease from $24.2 million in the previous year. The decline is attributed to broader CBD category softness and reduced marketing spend.
Cost of sales was $7.5 million, representing 38.4% of net sales, compared to 38% in the prior year. The increase in cost ratio was partially due to a one-time non-cash inventory write-down.
Operating expenses decreased by 36.4% to $15.3 million, reflecting management's efforts to rationalize costs, particularly in payroll and marketing.
The company reported an operating loss of $3.3 million, an improvement from the $22.5 million loss in the previous year, which included a $13.2 million impairment charge.
cbdMD's net loss before taxes was $3.7 million, compared to $22.9 million in the previous year. After preferred dividends, the net loss attributable to common shareholders was $7.7 million.
The company ended the fiscal year with $2.4 million in cash and cash equivalents and a working capital deficit of $1.1 million, impacted by accrued preferred dividends.
cbdMD's strategies for fiscal 2025 include product innovation, expanding revenue channels, and international expansion. The company launched a new line of functional mushroom supplements and entered the hemp-derived beverage category.
The filing highlights the company's focus on regulatory compliance and the challenges posed by the lack of a clear federal regulatory framework for CBD products.
cbdMD's management acknowledges the need for additional capital to fund operations and improve profitability, with ongoing efforts to simplify the capital structure and enhance shareholder value.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the cbdMD Inc. annual 10-K report dated December 18, 2024. To report an error, please email earnings@qz.com.